We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Status of PI3K/Akt/mTOR pathway inhibitors in lymphoma.
- Authors
Westin, Jason R.
- Abstract
The phosphatidylinositol-3-kinase (PI3K) pathway is well known to regulate a wide variety of essential cellular functions, including glucose metabolism, translational regulation of protein synthesis, cell proliferation, apoptosis, and survival. Aberrations in the PI3K pathway are among the most frequently observed in cancer, and include amplifications, rearrangements, mutations, and loss of regulators. As a net result of these anomalies, the PI3K pathway is activated in many malignancies, including in Hodgkin and non-Hodgkin lymphomas, and yields a competitive growth and survival advantage, increased metastatic ability, and resistance to conventional therapy. Numerous inhibitors targeting various nodes in the PI3K pathway are undergoing clinical development, and their current status in lymphoma will be the focus of this review.
- Publication
Clinical Lymphoma, Myeloma & Leukemia, 2014, Vol 14, Issue 5, p335
- ISSN
2152-2650
- Publication type
journal article
- DOI
10.1016/j.clml.2014.01.007